Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECTAR: Neoadjuvant Toripalimab Plus 9MW2821 in Localized UTUC
NCT07412171Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin in upper tract urothelial carcinoma (UTUC), sponsored by Peking University Third Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07412171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412171.